Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.
A global phase 2 study, AKITA, was initiated in 2022. Learn more about the clinical development of RMC-035.Read more
RMC-035, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.Read more
Acute kidney injury is a large market. 13 million people gloabally are affected every year.Read more
Guard Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted RMC-035 (ROSgard) Fast Track designation for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury.Read more
Guard Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted the company's Investigational New Drug (IND) application for the investigational drug RMC-035 (ROSgard). The approval enables expansion of the clinical development program for RMC-035 to the US, including the ongoing global and placebo-controlled Phase 2 study AKITA in cardiac surgery.Read more
Guard Therapeutics today announces that the first patient has been dosed in a Phase 1b clinical trial of the investigational drug RMC-035 (ROSgard) in kidney transplantation. The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC-035 has the potential to protect against acute kidney injuries. Full study results are expected to be available in the first half of 2023.Read more